BCL2 and acute myeloid leukemia: In vitro and clinical observation have suggested increased sensitivity of IDH1/2-mutant AML cells to pharmacologic BCL-2 inhibition induced by (R)-2-hydroxyglutarate-mediated inhibition of cytochrome c oxidase activity leading to lowering of the mitochondrial threshold to trigger apoptosis [83,84,85].